

**USC/Kenneth Norris Cancer Center Protocols  
Hematology Protocol Priority List  
Version Dated 05/03/2024 ds**

P – Pasadena NB – Newport Beach H – Hoag  
TM – Team Manager

\* - Protocol is Open to Accrual at Los Angeles General (LAGMC)

**Malignant Hematology**

**Leukemia**

**9L-16-10** T-cell Repertoire in Patients with AML. TM: C. Duran  
**\*9L-17-13** Ph1B AMG-232+Decitabine in AML TM: C. Duran  
**9L-17-16** Pharmacogenomics of age-specific, Asparaginase-induced hepatotoxicity ALL. TM: C. Duran  
**SUSPENDED\* 9L-18-9** Ph2 Ibrutinib + Blinatumomab in R-R B-Cell ALL. TM: C. Duran  
**9L-20-1** M3814 + MEC in Relapsed or Refractory AML. TM: C. Duran  
**\* 9L-20-8** A Study of PK, Safety, and Efficacy of ASTX727 + Venetoclax in AML. C. Duran  
**9L-21-1 (SUSPENDED)** Ph1a/1b Trial of CG-806 in Pts. With R/R AML. TM: C. Duran.  
**9L-21-7** Ph3 Rand. Double-Blind Study of SY-1425 + AZA vs Placebo + AZA in Newly Diagnosed, RARA-Positive Adult Pts with Higher-Risk MDS. TM: C. Duran  
**9L-22-1** Ph3 Rand, Double-Blind, Placebo-Controlled Study of Itolizumab in Combo w/ Corticosteroids for Initial Tx of aGVHD. TM: C. Duran  
**\* 9L-22-2** Ph2a Rand. Open-Label Study of ISIS 702843 in Pts w/ Phlebotomy Dependent Polycythemia Vera (PD-PV). TM: C. Duran  
**9L-22-3** Ph1/2A FIH Study of Menin-MLL (KMT2A) Inhibitor KO-539 in Pts w/ R/R AML. TM: C. Duran.  
**9L-22-5** Ph1/2, Open-Label Study of Oral TP-3654 in Pts w/ Intermediate or High-risk Primary or Secondary Myelofibrosis. TM: C. Duran  
**\* 9L-22-7** Assessment of Cognitive Function in Pts w/ MPNs. RC: I. Syed  
**9L-23-1** Ph2, Rand. Study of Curcumin vs Placebo on Inflammatory Cytokines, Symptoms & Disease Parametes in CCUS, LR-MDS, MPNs. TM: C. Duran  
**9L-23-3 (SUSPENDED)** Ph1/2 Study of HM43239 in Pts w/ R/R AML. TM: C. Duran  
**9L-23-4** Ph1 Study of Ven/Aza or Venetoclax in Combo w/ Ziftometinib or Standard Induction 7+3 Chemotx in Combo w/ Ziftometinib for Pts w/ AML. TM: C. Duran  
**9L-23-5** Ph 1/2, Open-label, Dose-Escalation & Expansion Cohort Study of SNDX-5613 in R/R Leukemias Harboring MLL/KMT2A Gene Rearrangement or NPM1 Mutation. TM: C. Duran  
**9L-23-6** Ph1/2 Study of INCB000928 as Monotx or in Combo w/ Ruxolitinib in Pts w/ Anemia Due to Myeloproliferative Disorders. TM: C. Duran

**9L-23-8** Ph2 Venetoclax in Combo w/ ASTX727, for CMML and Other MDS/MPN w/ Excess Blasts (VICTORY-MDS/MPN). TM: C. Duran  
**9L-23-9** Establishment of Biorepository for Adult Leukemia for NCCC. TM: C. Duran

**Non-Hodgkin's Lymphoma**

**13NHL-22-3** Ph1 Study of CNTY-101 in Subjects w/ R/R CD19+ B-Cell Malignancies. TM: C. Duran  
**13NHL-23-1** Ph1a/1b Trial in R/R T-cell NHL of ST-001 (fenretinide phospholipid suspension 12.mg/mL IV). TM: C. Duran  
**13NHL-23-2** Rand/ Open-Label, Ph III, Mosunetuzumab + Polatuzumab Vedotin vs Rituximab +Gemcitabine + Oxaliplatin in R/R Aggressive B-Cell NHL. TM: C. Duran  
**13NHL-23-3** Ph3 Study of Epcoritamab in Combo w/ R2 Compared to R2 Alone in Subjs. w/ R/R Follicular Lymphoma (EPCORE FL-1). TM: C. Duran  
**13NHL-23-4** Ph 3, Rand/ Open-Label, Epcoritamab + R-CHOP vs. R-CHOP in Newly Diagnosed DLBC. TM: C. Duran

**Hodgkin's Disease**

**Myeloma**

**\* 16M-18-2** Ph2 Low-Dose (4Gy) Palliative RadioTx in the T/M of Symptomatic Bone metastases from MM. TM: C. Duran  
**\* 16M-22-1 (SUSPENDED)** Ph1b/2 Study of Standard Doses of Bortezomib and Pembro +/- Reovirus (Pelareorep) Combo Tx in Pts. w/ R/R MM (AMBUSH Study). TM: C. Duran  
**16M-23-1** Intermediate-Size Population EAP for cilta-cel OOS in MM. TM: C. Duran

**Multiple Sites or Special Studies**

**\* 0S-15-16** Immunology Specimen Collection from Cx Pts, Pts w/ Hematologic Diangoses and Healthy Normal Controls. RC: I. Syed  
**0S-22-9** ABC008 in T-Large Granular Lymphocyte Leukemia (T-LGLL). TM: C. Duran  
**9L-10-3** Heme Tissue Repository. PI: Dr. Preet Chaudhary  
**9L-16-10** T-cell Repertoire in Patients with AML. PI: Houda Alachkar, MD  
**9L-17-16** Pharmacogenomics of Age-Specific, Asparaginase-induced hepatotoxicity in Pts w/ ALL. PI: Houda Alachkar, MD  
**9L-22-7** Assessment of Cognitive Function in Pts w/ Myeloproliferative Neoplasms. TM: C. Duran  
**16M-23-1** EAP for Cilta-cel OOOS in Pts w/ Multiple Myeloma. TM: C. Duran / Ali (BMT) / Jones (BMT)

**Non-Malignant Hematology**

**Non-Therapeutic**

**\* NC-HEM-05-4** Hematology Database. RC: I. Syed.  
**NC-HEM-09-2** PNH Registry. TM: C. Duran

**Therapeutic**

**\* NC-HEM-19-7** Rand/ Double blinded Efficacy & Safety of M281 in Warm Autoimmune Hemolytic Anemia. TM: C. Duran  
**NC-HEM-22-1** Ph3 Trial of Oral BID LNP023 in Adult ahUS Pts. Naïve to Complement Tx. TM: C. Duran  
**\* NC-HEM-23-1** Ph1b Open-Label Study of ALPN-303 in Subjects w/ Autoimmune Cytopenias (RUBY-4). TM: C. Duran  
**NC-HEM-23-4** Caplacizumab and Immunosuppressive Tx w/o 1L Therapeutic Plasma Exchange in Adults w/ Immune-Mediated Thrombotic Thrombocytopenic Purpura. TM: C. Duran  
**NC-HEM-23-5** Ph3 Rand. Double-Blind Placebo-Controlled Study of Obexelimab in Pts w/ wAIHA (SAPHAIRE). TM: C. Duran  
**NC-HEM-23-6** Roll-Over Extension Program of Iptacopan (LNP023) in Pts w/ PNH who have Completed PNH Ph2/3 Studies. TM: C. Duran